Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ulrich Germing

Showing results (71-80 of 339) with videos related to

Pageof 34
Sort By:
Leukemia Research|June 29, 2011
Incidence and prevalence of myelodysplastic syndromes: data from the Düsseldorf MDS-registryJudith Neukirchen, Wilma M Schoonen, Corinna Strupp, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 13, 2006
Secondary myelodysplastic syndrome following long-term treatment with azathioprine in patients with multiple sclerosisNorman Putzki, Sabine Knipp, Tim Ramczykowski, et al.
Leukemia|June 28, 2018
Diagnostic algorithm for lower-risk myelodysplastic syndromesGhulam J Mufti, Donal P McLornan, Arjan A van de Loosdrecht, et al.
Leukemia Research|July 26, 2005
Adequate cytogenetic examination in myelodysplastic syndromes: analysis of 529 patientsChristian Steidl, Rainer Steffens, Winfried Gassmann, et al.
Leukemia Research|February 3, 2009
Impact on survival of different treatments for myelodysplastic syndromes (MDS)Kathrin Nachtkamp, Andrea Kündgen, Corinna Strupp, et al.
Blood|January 25, 2007
High frequency of the JAK2 V617F mutation in patients with thrombocytosis (platelet count>600x109/L) and ringed sideroblasts more than 15% considered as MDS/MPD, unclassifiableNorbert Gattermann, Johan Billiet, Ralf Kronenwett, et al.
Hematological Oncology|June 21, 2007
Prognostic factors for patients with acute myeloid leukaemia or high-risk myelodysplastic syndromes undergoing myeloablative or non-myeloablative allogeneic blood stem cell transplantationThorsten Graef, Matthias Vaupel, Roland Fenk, et al.
Leukemia Research|May 9, 2012
Improved survival in MDS patients receiving iron chelation therapy - a matched pair analysis of 188 patients from the Düsseldorf MDS registryJudith Neukirchen, Frank Fox, Andrea Kündgen, et al.
Bone Marrow Transplantation|September 3, 2020
Wilm's Tumor 1-guided preemptive treatment with hypomethylating agents for molecular relapse of AML and MDS after allogeneic transplantationChristina Rautenberg, Anika Bergmann, Sabrina Pechtel, et al.
Haematologica|April 2, 2009
The hematopoietic stem cell transplantation comorbidity index is of prognostic relevance for patients with myelodysplastic syndromeEsther Zipperer, Daniela Pelz, Kathrin Nachtkamp, et al.
Pageof 34

Showing results (71-80 of 339) with videos related to

Sort By:
Pageof 34
Leukemia Research|June 29, 2011
Incidence and prevalence of myelodysplastic syndromes: data from the Düsseldorf MDS-registryJudith Neukirchen, Wilma M Schoonen, Corinna Strupp, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 13, 2006
Secondary myelodysplastic syndrome following long-term treatment with azathioprine in patients with multiple sclerosisNorman Putzki, Sabine Knipp, Tim Ramczykowski, et al.
Leukemia|June 28, 2018
Diagnostic algorithm for lower-risk myelodysplastic syndromesGhulam J Mufti, Donal P McLornan, Arjan A van de Loosdrecht, et al.
Leukemia Research|July 26, 2005
Adequate cytogenetic examination in myelodysplastic syndromes: analysis of 529 patientsChristian Steidl, Rainer Steffens, Winfried Gassmann, et al.
Leukemia Research|February 3, 2009
Impact on survival of different treatments for myelodysplastic syndromes (MDS)Kathrin Nachtkamp, Andrea Kündgen, Corinna Strupp, et al.
Blood|January 25, 2007
High frequency of the JAK2 V617F mutation in patients with thrombocytosis (platelet count>600x109/L) and ringed sideroblasts more than 15% considered as MDS/MPD, unclassifiableNorbert Gattermann, Johan Billiet, Ralf Kronenwett, et al.
Hematological Oncology|June 21, 2007
Prognostic factors for patients with acute myeloid leukaemia or high-risk myelodysplastic syndromes undergoing myeloablative or non-myeloablative allogeneic blood stem cell transplantationThorsten Graef, Matthias Vaupel, Roland Fenk, et al.
Leukemia Research|May 9, 2012
Improved survival in MDS patients receiving iron chelation therapy - a matched pair analysis of 188 patients from the Düsseldorf MDS registryJudith Neukirchen, Frank Fox, Andrea Kündgen, et al.
Bone Marrow Transplantation|September 3, 2020
Wilm's Tumor 1-guided preemptive treatment with hypomethylating agents for molecular relapse of AML and MDS after allogeneic transplantationChristina Rautenberg, Anika Bergmann, Sabrina Pechtel, et al.
Haematologica|April 2, 2009
The hematopoietic stem cell transplantation comorbidity index is of prognostic relevance for patients with myelodysplastic syndromeEsther Zipperer, Daniela Pelz, Kathrin Nachtkamp, et al.
Pageof 34